Could A Club Drug Offer 'Almost Immediate' Relief From Depression?
There's no quick fix for severe depression.
Although antidepressants like Prozac have been around since the 1970s, they usually take weeks to make a difference. And for up to 40 percent of patients, they simply don't work.
As a result, there are limited options when patients show up in an emergency room with suicidal depression.
The doctors and nurses at Ben Taub General Hospital in Houston say they see this problem every day.
You can get a sense of what they're up against by visiting the cavernous, bustling emergency center at Ben Taub, which is part of the massive Texas Medical Center. More than 100,000 patients a year get emergency care here, and about 5,000 of them need psychiatric evaluation.
The hospital's 24-hour Psychiatric Emergency Center gets a steady stream of people with suicidal depression, says Charlzetta McMurray-Horton, who is in charge of mental health nursing.
"If the police bring them in, they're going to come through this door," McMurray-Horton says, pointing to one entrance. "If the ambulance brings them in, they're going to come through this door," she says, pointing to a different entrance.
And one of the challenges in treating these severely depressed patients is that there simply isn't any drug that provides quick relief, says Anu Matorin, medical director of the Psychiatric Emergency Center.
Matorin talks about one recent patient. The woman had suffered bouts of depression since college, Matorin says. But after she had a baby, it became severe. She stopped eating and sleeping. She began to think about suicide.
Finally, the woman made a desperate call to her mother, Matorin says.
"She was very emotional, very tearful, not making sense," Matorin says. "She says, 'I just can't take it anymore. I don't know how to feed the child.' The mother could hear the infant crying in the background."
The family called 911, and the woman arrived at the hospital with a police escort. Matorin says she evaluated the woman and put her on antidepressants.
Then came the hard part, Matorin says. She knew the drugs might help the woman eventually. But they weren't going to do anything about her suicidal thoughts during the next few critical days.
So Matorin did the only thing she could for her patient. She admitted her to the hospital's locked inpatient unit.
I ask to see the facility, so McMurray-Horton takes me there.
'Keep Them Safe, Keep Them Alive'
The unit can handle 20 patients, and its main room is warmer, softer and more colorful than you might expect. Think Holiday Inn, without any sharp objects or hard edges.
But there's no avoiding the fact that this is a place where safety is paramount and privacy isn't, says McMurray-Horton. Shatterproof plastic windows around the nurses' station provide unobstructed sightlines to pretty much everywhere.
"Patients don't want to be here," says McMurray-Horton, explaining that about three-quarters of them are in the unit because they have been deemed a threat to themselves or someone else.
So it's not surprising that our tour of the unit is interrupted by the loud protests of one enraged patient.
Units like this are necessary in part because drugs for depression don't work fast enough to help someone in the early days of a crisis, Matorin says.
And McMurray-Horton says staff members here have a simple goal for patients in crisis: "Keep them safe, keep them alive until they're in a different space."
Counseling can help, McMurray-Horton says. So can family. And she says most people in crisis just start to feel better after a few days in a place where staff make sure that "they stay in, and the world stays out."
That was certainly true of the depressed young mother that Matorin admitted. She got better and went home several days later.
But that woman probably could have skipped the hospital stay altogether if the drugs used to treat depression were as quick and effective as, say, painkillers, Matorin says.
If drugs were more effective, "I think it would transform psychiatric care and really eliminate some of the stigma and fear and concern about treatment," she says.
'A Completely Different Mechanism'
A growing number of scientists think it won't be long before psychiatric care is transformed.
And they are particularly excited about an experimental drug that is being tried in the NeuroPsychiatric Center next to Ben Taub hospital.
It's here that drug researchers are studying a drug that's unlike anything now used to treat depression. And they're giving it to patients who haven't done well on existing drugs.
One of these patients is Heather Merrill, who speaks to me in a small conference room that is part of the large and very busy outpatient clinic.
Merill is 41, with three kids and a nice house in the suburbs.
"I've suffered from depression for most of my adult life," she says. "It got to the point where I kind of felt like there wasn't going to be anything that was going to be able to help me."
At times her depression gets so bad that she can't take care of her family or even herself, she says. And that's how she was feeling the day before, she says, when doctors placed an IV in her arm and began to administer a drug.
Because it was part of an experiment, there were two possibilities. The drug could have been just a sedative. Or it might have been something called ketamine.
Ketamine has been used for decades as an anesthetic. It also has become a wildly popular but illegal club drug known as "Special K."
Mental health researchers got interested in ketamine because of reports that it could make depression vanish almost instantly.
In contrast, drugs like Prozac take weeks or even months. And the frustrating thing is that depression medications really haven't changed much since Prozac arrived in the 1970s, says Sanjay Mathew from Baylor College of Medicine, who is in charge of the ketamine study at Ben Taub.
"Everything since then has been essentially incremental," he says. "There have been tweaks of existing molecules."
But ketamine represents much more than a tweak, Mathews says.
"It's a completely different mechanism," he says. "And the focus is on really rapidly helping someone get out of a depressive episode."
'No More Fogginess. No More Heaviness.'
Heather Merrill says she's pretty sure it was ketamine that flowed into her veins 24 hours earlier.
"It was almost immediate, the sense of calmness and relaxation," she says.
Some of the doctors think she might be right.
"Her demeanor has changed tremendously," says Dr. Asim Shah, who directs the mood disorder program at Ben Taub. "She looks like a happy person who is genuinely happy, whereas before the study, she looked very down, very withdrawn, sort of almost tearful."
But of course, nobody knows whether Merrill actually got ketamine. That information will be kept secret until the study is done, months from now.
So I decide to see how Merrill's experience compares with the experiences of people who definitely took ketamine for depression.
I talk to Carlos Zarate, who does ketamine research at the NIH and has never met Merrill. Zarate says patients typically say, " 'I feel that something's lifted or feel that I've never been depressed in my life. I feel I can work. I feel I can contribute to society.' And it was a different experience from feeling high. This was feeling that something has been removed."
I compare this to what Merrill said about her experience: "No more fogginess. No more heaviness. I feel like I'm a clean slate right now. I want to go home and see friends or, you know, go to the grocery store and cook the family dinner."
The similarities are hard to ignore.
And researchers say the consistent patient reactions have actually made it more difficult to do good studies of ketamine. The drug's effects are so powerful and distinctive, they say, it's hard to prevent doctors and patients in an experiment from figuring out who got the drug and who didn't.
Jon Hamilton's follow-up report looks at research that seeks to unravel how ketamine acts on depression symptoms in an effort to development faster-acting drugs.
Copyright 2020 NPR. To see more, visit https://www.npr.org.